Oral LeukoplakiaNCT04251845
Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia
A study testing topical melatonin in people with Oral Leukoplakia, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.
Trial summary
Oral leukoplakia is the most commonly occurring oral premalignant disorder. It has an overall prevalence rate of 1-4% with highest prevalence rate of 10.54% in Asian countries. The management of leukoplakia includes conventional as well as surgical modalities. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Oral Leukoplakia
- What is being tested?
- topical melatonin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 66 participants
- Where
- 1 siteIndia
- Study dates
- 1 Feb 2020to 30 Sep 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Clinically and histologically proven cases of leukoplakia associated with tobacco.
- With age 18 years and above. Willing and able to participate in the study and signed informed consent.
Who cannot join
- Patients suspicious of malignant transformation of the lesion with frank ulceration or growth.
- Patients consuming or have consumed drugs for treatment of leukoplakia.
- Patients who have red or white lesions persisting after radiotherapy treatment
- Patients with acquired and congenital immunodeficiency disorders like AIDS, chemotherapy, addiction to injectable opioids and any other significant medical or systemic or autoimmune conditions.
- Pregnancy or lactation phase.
- Known allergy to melatonin.
Trial locations and contacts
1 site in 1 country.
India1 site, 1 recruiting
- Recruiting
Post graduate institute of dental sciences
Rohtak, Haryana, 124001
Sanjay Tewari, MDS, 01262283876, principalpgids@yahoo.in
About this study
Official title: Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia: A Randomized Placebo Controlled Study
Oral leukoplakia is the most commonly occurring oral premalignant disorder. It has an overall prevalence rate of 1-4% with highest prevalence rate of 10.54% in Asian countries. The management of leukoplakia includes conventional as well as surgical modalities. The conventional approaches include Beta Carotene, Lycopene, ascorbic acid, alpha tocopherol, retinoids. But, no significant results are documented on regression rate and prevention of recurrence of the lesions.
Melatonin chemically N-acetyl-5-methoxytryptamine is a hormone produced in the pineal gland. It is synthesized from the amino acid, tryptophan. The basic physiological function of melatonin is to control day night cycle and hence is commonly used in insomnia, jet lag and some other psychological disorders.
Read more
Melatonin has a potent antioxidant effect and other actions such as modulation of cell cycle and induction of apoptosis, inhibition of telomerase activity, inhibition of metastasis, prevention of circadian disruption, anti-angiogenesis and stimulation of cell differentiation
To date, no treatment modality has demonstrated its clear superiority for leukoplakia. There are many pathways by which melatonin can be used beneficially for management oral leukoplakia.
Read the detailed description
The World Health Organization (W.H.O). defines oral potentially malignant disorders (OPMDs) as "A histologically proven lesion that is associated with a significantly increased risk of malignant transformation."Oral leukoplakia is the most commonly occurring oral potentially malignant disorder. According to World Health Organisation (WHO), it is defined as "predominantly white plaques of questionable risk having excluded other known diseases or disorders that carry no increased risk for cancer."Leukoplakia has a prevalence rate of 1-4% in the world and 0.2% to 5.2% in Indian Subcontinent, with a malignant transformation rate (MTR) of 0.13% to 10%.
The risk factors include- a) Smokeless and smoking tobacco b) Ultraviolet radiation c) Associated infections like candida, Human papilloma virus (HPV), Epstein Bar Virus (EBV) d) Synergistic effects of alcohol e) Epithelial atrophy due to conditions like syphilis, vitamin deficiencies, iron deficiencies f) trauma.
There are mainly two types of leukoplakia- homogenous and non-homogenous. When widespread or multiple patches of leukoplakia are noted, the term proliferative verrucous leukoplakia (PVL) is used. The homogenous leukoplakias have a lower risk of malignant transformation (0.6%-5%) as compared to non-homogenous (20-25%), while its highest for PVL (61%). The MTR is also high in lesions of size more than 200 mm, tongue and floor of mouth, female patients, old age, severe dysplasia, HPV and candida associated and DNA Aneuploidy.The presence of dysplasia in the lesions of leukoplakia increases the incidence of malignancy by 30 %.
On exposure to carcinogens, tissue cells proliferate and shrink the cytosolic capacity as an adaptation which can be appreciated as hyperplasia of epithelium in histological sections. The persistence of irritant factor leads to cellular degeneration and atrophy, thus further progressing into irreversible cell damages, leading to apoptosis, genetic damages and malignant transformation. There are many studies which suggest the role of reactive oxygen species and reactive nitrogen species in the initiation and progression of carcinogenesis. The generation of oxidative stresses further lead to DNA damage in later stages. Studies are also done which shows decrease in the serum superoxide dismutase, glutathione reductase, glutathione peroxidase and catalase in the patients of leukoplakia.
It is a well-established fact that, oral cancer development is a two-step process which constitutes the emergence of premalignant disorders and their subsequent conversion into cancer. The asymptomatic nature of leukoplakia makes the scenario more difficult as they go unnoticed, leading to their diagnosis only in the stages of malignant conversion. Medical as well as surgical management of cancer causes a deterioration in quality of life of patients due to potentially harmful side effects. Thus, more focus is necessary for chemoprevention of leukoplakia lesions at the premalignant stages thereby preventing its malignant transformation.
The management of leukoplakia includes both conventional as well as surgical modalities. The conventional approaches include Beta Carotene, Lycopene, ascorbic acid, alpha tocopherol, retinoids. But, no significant results are documented on regression rate and prevention of recurrence of the lesions. Other treatment modalities under the experimental trials include extracts of green tea, inhibitors of cyclo-oxygenase 2, epidermal growth factors, peroxisome proliferator. However, there is no generally approved standard systemic therapy so far. Local surgical procedures include photodynamic therapy, laser therapy, cryotherapy and excision.
Melatonin chemically N-acetyl-5-methoxytryptamine is a hormone produced in the pineal gland. It is synthesised from the amino acid, tryptophan. The basic physiological function of melatonin is to control day night cycle and hence is commonly used in insomnia, jet lag and some other psychological disorders.
Melatonin has been proved to exert oncostatic properties through various mechanisms like potent antioxidant effect, antiproliferative functions, stimulation of anticancer immunity, antiangiogenic effects, modulation of oncogene expression and anti-inflammatory. It also exhibits anti candidal and radioprotective effect on the oral mucosa. Thus, melatonin may be helpful in treatment of oral leukoplakia.
Therefore, this study intends to evaluate the effect of topical application of melatonin on clinical response as well as on histopathological and immunohistochemistry findings of leukoplakia.
- Conditions
- Oral Leukoplakia
- Being tested
- topical melatonin, PLACEBO
- Medical subject headings
- Leukoplakia, Oral
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
topical melatoninDietary supplement
Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
PLACEBOOther
Topical application of placebo once daily for 6 weeks with a follow up for 3 months
| Study group | Role | What they receive |
|---|---|---|
| Trial group | Active comparator | Intervention : Topical Melatonin(3%) at dosage of 15 mg once daily Receives: Dietary Supplement: topical melatonin |
| Control Group | Placebo comparator | Intervention : Placebo once daily Receives: Other: PLACEBO |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the size of the lesion.
measurement of the lesion and scored according to RECIST criteria
Measured: four and a half months
Secondary outcomes (2)
Degree of dysplasia
Grading of dysplasia according to Speight classification (2007).
Measured: four and a half months
Expression of immunopositivity of ki67 cells in the lesion.
Percentage of a total number of Ki-67 positive cells to a total number of cells will be primarily deducted.
Measured: four and a half months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2020
- Study start1 Feb 2020 (estimated)
- Primary completion30 Aug 2020 (estimated)
- Study completion30 Sep 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral LeukoplakiaStudies of the same condition, open and under way.
- More trials run by Postgraduate Institute of Dental Sciences RohtakThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 66 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Postgraduate Institute of Dental Sciences Rohtak
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04251845
- Sponsor's protocol ID
- Shubhangi OMR
- Status last verified
- Jan 2020
- First submitted
- 30 Jan 2020
- Last updated
- 5 Feb 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia: A Randomized Placebo Controlled Study
- ClinicalTrials.gov ID
- NCT04251845
- Acronym / sponsor ID
- Shubhangi OMR
- Conditions
- Oral Leukoplakia
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 66 participants (estimated)
- Lead sponsor
- Postgraduate Institute of Dental Sciences RohtakUniversity, hospital or other
- Study start
- 1 Feb 2020 (estimated)
- Primary completion
- 30 Aug 2020 (estimated)
- Study completion
- 30 Sep 2020 (estimated)
- First posted
- 5 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Oral leukoplakia is the most commonly occurring oral premalignant disorder. It has an overall prevalence rate of 1-4% with highest prevalence rate of 10.54% in Asian countries. The management of leukoplakia includes conventional as well as surgical modalities. The conventional approaches include Beta Carotene, Lycopene, ascorbic acid, alpha tocopherol, retinoids. But, no significant results are documented on regression rate and prevention of recurrence of the lesions.
Melatonin chemically N-acetyl-5-methoxytryptamine is a hormone produced in the pineal gland. It is synthesized from the amino acid, tryptophan. The basic physiological function of melatonin is to control day night cycle and hence is commonly used in insomnia, jet lag and some other psychological disorders.
Melatonin has a potent antioxidant effect and other actions such as modulation of cell cycle and induction of apoptosis, inhibition of telomerase activity, inhibition of metastasis, prevention of circadian disruption, anti-angiogenesis and stimulation of cell differentiation
To date, no treatment modality has demonstrated its clear superiority for leukoplakia. There are many pathways by which melatonin can be used beneficially for management oral leukoplakia.
Detailed description
The World Health Organization (W.H.O). defines oral potentially malignant disorders (OPMDs) as "A histologically proven lesion that is associated with a significantly increased risk of malignant transformation."Oral leukoplakia is the most commonly occurring oral potentially malignant disorder. According to World Health Organisation (WHO), it is defined as "predominantly white plaques of questionable risk having excluded other known diseases or disorders that carry no increased risk for cancer."Leukoplakia has a prevalence rate of 1-4% in the world and 0.2% to 5.2% in Indian Subcontinent, with a malignant transformation rate (MTR) of 0.13% to 10%.
The risk factors include- a) Smokeless and smoking tobacco b) Ultraviolet radiation c) Associated infections like candida, Human papilloma virus (HPV), Epstein Bar Virus (EBV) d) Synergistic effects of alcohol e) Epithelial atrophy due to conditions like syphilis, vitamin deficiencies, iron deficiencies f) trauma.
There are mainly two types of leukoplakia- homogenous and non-homogenous. When widespread or multiple patches of leukoplakia are noted, the term proliferative verrucous leukoplakia (PVL) is used. The homogenous leukoplakias have a lower risk of malignant transformation (0.6%-5%) as compared to non-homogenous (20-25%), while its highest for PVL (61%). The MTR is also high in lesions of size more than 200 mm, tongue and floor of mouth, female patients, old age, severe dysplasia, HPV and candida associated and DNA Aneuploidy.The presence of dysplasia in the lesions of leukoplakia increases the incidence of malignancy by 30 %.
On exposure to carcinogens, tissue cells proliferate and shrink the cytosolic capacity as an adaptation which can be appreciated as hyperplasia of epithelium in histological sections. The persistence of irritant factor leads to cellular degeneration and atrophy, thus further progressing into irreversible cell damages, leading to apoptosis, genetic damages and malignant transformation. There are many studies which suggest the role of reactive oxygen species and reactive nitrogen species in the initiation and progression of carcinogenesis. The generation of oxidative stresses further lead to DNA damage in later stages. Studies are also done which shows decrease in the serum superoxide dismutase, glutathione reductase, glutathione peroxidase and catalase in the patients of leukoplakia.
It is a well-established fact that, oral cancer development is a two-step process which constitutes the emergence of premalignant disorders and their subsequent conversion into cancer. The asymptomatic nature of leukoplakia makes the scenario more difficult as they go unnoticed, leading to their diagnosis only in the stages of malignant conversion. Medical as well as surgical management of cancer causes a deterioration in quality of life of patients due to potentially harmful side effects. Thus, more focus is necessary for chemoprevention of leukoplakia lesions at the premalignant stages thereby preventing its malignant transformation.
The management of leukoplakia includes both conventional as well as surgical modalities. The conventional approaches include Beta Carotene, Lycopene, ascorbic acid, alpha tocopherol, retinoids. But, no significant results are documented on regression rate and prevention of recurrence of the lesions. Other treatment modalities under the experimental trials include extracts of green tea, inhibitors of cyclo-oxygenase 2, epidermal growth factors, peroxisome proliferator. However, there is no generally approved standard systemic therapy so far. Local surgical procedures include photodynamic therapy, laser therapy, cryotherapy and excision.
Melatonin chemically N-acetyl-5-methoxytryptamine is a hormone produced in the pineal gland. It is synthesised from the amino acid, tryptophan. The basic physiological function of melatonin is to control day night cycle and hence is commonly used in insomnia, jet lag and some other psychological disorders.
Melatonin has been proved to exert oncostatic properties through various mechanisms like potent antioxidant effect, antiproliferative functions, stimulation of anticancer immunity, antiangiogenic effects, modulation of oncogene expression and anti-inflammatory. It also exhibits anti candidal and radioprotective effect on the oral mucosa. Thus, melatonin may be helpful in treatment of oral leukoplakia.
Therefore, this study intends to evaluate the effect of topical application of melatonin on clinical response as well as on histopathological and immunohistochemistry findings of leukoplakia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Trial group | Active comparator | Dietary Supplement: topical melatoninIntervention : Topical Melatonin(3%) at dosage of 15 mg once daily |
| Control Group | Placebo comparator | Other: PLACEBOIntervention : Placebo once daily |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Clinically and histologically proven cases of leukoplakia associated with tobacco.
- With age 18 years and above. Willing and able to participate in the study and signed informed consent.
Key exclusion criteria (6 listed)
- Patients suspicious of malignant transformation of the lesion with frank ulceration or growth.
- Patients consuming or have consumed drugs for treatment of leukoplakia.
- Patients who have red or white lesions persisting after radiotherapy treatment
- Patients with acquired and congenital immunodeficiency disorders like AIDS, chemotherapy, addiction to injectable opioids and any other significant medical or systemic or autoimmune conditions.
- Pregnancy or lactation phase.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| topical melatoninTopical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months | Dietary supplement | Trial group |
| PLACEBOTopical application of placebo once daily for 6 weeks with a follow up for 3 months | Other | Control Group |
Primary outcome
Change in the size of the lesion.
Time frame: four and a half months
measurement of the lesion and scored according to RECIST criteria
2 secondary outcomes
Degree of dysplasia
Time frame: four and a half months
Expression of immunopositivity of ki67 cells in the lesion.
Time frame: four and a half months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2020.
Related trials for Oral Leukoplakia
RecruitingObservational study
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers
Oral Potentially Malignant Disorders, Oral Lichen Planus
Active, not recruitingPhase 2
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
Erythroplakia, Oral Leukoplakia
Active, not recruiting
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
Erythroplakia, Fanconi Anemia
RecruitingPhase 2
Pembrolizumab in Treating Participants With Leukoplakia
Erythroleukoplakia, Leukoplakia
RecruitingPhase 2
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
Oral Leukoplakia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing topical melatonin in people with Oral Leukoplakia, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sanjay Tewari (01262283876, principalpgidsrohtak@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the size of the lesion. (time frame: four and a half months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2020.